Healthcare

HR 6945 clarifies that states may use federal grants under Section 403 of the Social Security Act to support pregnancy centers meeting specific criteria. These centers must promote protecting both mother and unborn child life while providing services like counseling, pregnancy testing, and material support (e.g., diapers, baby clothes). The bill explicitly prohibits interpreting existing law as barring such funding for eligible centers. It does not create new funding but defines which pregnancy resource organizations qualify for existing grants.

This bill requires colleges receiving federal student aid to provide clear information about pregnancy-related accommodations and resources to all students annually. It mandates institutions to send emails to enrolled students each academic year, include details in student handbooks and orientations, and display the information at health centers and on websites. The disclosure must cover campus/community resources for pregnant students, available accommodations, and how to file complaints under Title IX regarding pregnancy discrimination. The bill does not create new rights but ensures existing protections and resources are communicated to students. It directly affects all participating colleges and pregnant students enrolled in higher education programs.

The Lower Health Care Premiums for All Americans Act (HR 6703) requires large health plans (with at least 100 average participants) and pharmacy benefit managers to submit detailed reports every six months on drug spending, rebates, and out-of-pocket costs. These reports include specific information on drug costs, rebates received, pricing structures, and spending patterns, making this information available to plan sponsors and participants. The bill also establishes new rules for association health plans and health reimbursement arrangements to expand affordable coverage options for workers and self-employed individuals. The primary goal of these reporting requirements is to increase transparency around health care costs, allowing consumers and employers to make more informed decisions about health coverage. The bill does not directly set or reduce premiums but provides data that could inform future premium negotiations and decisions.

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.